ea0029p1076 | Neuroendocrinology | ICEECE2012
Athanasoulia A.
, Sievers C.
, Ising M.
, Brockhaus A.
, Yassouridis A.
, Stalla G.
, Uhr M.
Introduction: Treatment with dopamine agonists in patients with prolactinomas and Parkinsons disease is associated with central side effects. Central side effects may depend on a substances ability to pass the blood-brain barrier which can be actively controlled by transporter molecules such as the P-glycoprotein encoded by the ABCB1 gene.Aim of the study: To determine whether cabergoline is transported by the P-glycoprotein and whether polym...